Saroglitazar

Name: Saroglitazar in Primary biliary cholangitis: Peroxisome Proliferator-Activated receptor agonists
Published: 2026-09-14T15:39:06-04:00

Primary biliary cholangitis

Manufacturer: Zydus Therapeutics
Regulatory submission: NDA submitted by May 2026
Launch: Anticipated in April 2027, the start of Zydus fiscal year 2028
Last updated: September 19, 2026

Section

Product information and disease description Place of product in therapy Approaches to treatment Current treatment options and standard of care

Peroxisome Proliferator-Activated receptor agonists

2 evidence topics · 4 sources

Comparator prescribing information: elafibranor

“The recommended dosage is 80 mg orally once daily with or without food.” (opens the source at this quote in a new tab)

Comparator prescribing information: seladelpar

“The recommended dosage of LIVDELZI is 10 mg orally once daily.” (opens the source at this quote in a new tab)
“Administer LIVDELZI with or without food.” (opens the source at this quote in a new tab)